B. A patient who meets the criteria for admission to the category of patients whose treatment is subject to a cooperative agreement and who chooses not to participate in a collaborative procedure informs the prescriber of his refusal to participate in such a cooperation procedure. A prescriber may choose that a patient does not participate in a collaborative procedure by contacting the pharmacist or his designated alternative pharmacists or by documenting the patient`s prescription. “Patients are less likely to receive preventive health care [and] participate in community practice conventions,” he said. “Many people may not face the health care system until a health problem becomes critical.” WADA offers several suggestions on its website to help physicians assess the pros and cons of physician-pharmacist collaboration. Avery said that at the time of publishing his 2012 study, many of his colleagues were skeptical of the collaboration between the doctor and the pharmacist. However, much of these doubts have subsided. “There were concerns about the value of the intervention and its impact on the workload,” he said. “But we have achieved the positive results of the study and pharmacists are trained in educational public relations, so they are able to provide evidence-based responses to family physician requests. The intervention has a relatively small impact on family physicians, pharmacists do a lot of the work. “These results suggest that a model of care based on a well-established team involving pharmacists can be implemented in a large number of very different offices to reduce racial differences in BP control,” Carter said.
One of the obstacles to increasing the reception of pharmacists and doctors is that, according to Tomaka, patients do not want to add another doctor to their contact list. “Medication has evolved over the last 40 years from relatively unspecific to mild, for us now very powerful, very specific receptor therapy drugs, where pharmacists are the only ones who can find inappropriate or dangerous use,” he said. “While it is useful to formalize the formalized cooperation process, we need a lot of infantry to become a reality.” “There is some hesitation behind this model,” Norman Tomaka, BS, PharmMS, FAPhA, pharmacist at Consultant Pharmacist Services in Florida, said in an interview. Some members of the medical community are concerned that collaboration could drive up health costs, but data on health outcomes from other countries show that this reduces health costs. “Pharmacists have rarely been seen in the past as possible solutions to gaps in chronic disease control,” he said. “However, at national social meetings such as the American Heart Association or when convening expert committees, collaboration with pharmacists is often cited as an important strategy for improving care,” Carter said. “The medical community, especially primary care, is strongly supportive of this initiative, and [non-federal] payment structures are emerging for pharmacists, who are integrated into medical practices.” “There is a disconnect between the doctor and in the trenches and the agencies and bureaucracies that are not yet convinced, although I think they are now much more aware of the value of pharmacists,” he said. “I hope that a federal payment model will become a reality, but it`s hard to say if it will ever happen.” For pharmacists to participate in these collaborations, they need access to the patient`s electronic medical records,” said McCombs. In an article on health issues, Thomas Bodenheimer, MD, MPH, Professor of Family and Community Medicine at the University of California, San Francisco, and Mark D.